Clearly, reducing the intensity of inflammation with colchicine has been shown to correlate with incremental reduction in MACE rates in patients with ASCVD.5 Do other apoB-containing lipoproteins besides Lp(a) correlate with risk and should they be treated? Here, APOB is linked to atherosclerosis.